Mettler-Toledo International Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Life Sciences Tools and Services | Market Cap: ₹23.5K Cr
- The company expects local currency sales growth of approximately 4% for full year 2026, including about 1.5% contribution from acquisitions in H1 and less than 8% for the full year. - **Full-year 2026 local currency sales growth**: Approximately 4%, including about 1.5% contribution from acquisitions in H1 and less than 8% for full year.
From Mettler-Toledo International Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹1,163.5
Market Cap
₹23.5K Cr
P/E Ratio
25.9
Revenue Rank
Margin Rank
How does Mettler-Toledo International Inc. rank in Life Sciences Tools and Services?
Compare Mettler-Toledo International Inc. against every Life Sciences Tools and Services company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →The company expects local currency sales growth of approximately 4% for full year 2026, including about 1.5% contribution from acquisitions in H1 and less than 8% for the full year. (Page 3)
- →There is optimism for growth in the second half of 2026, supported by a stronger sales pipeline and improving customer activity despite caution in the first half due to geopolitical uncertainty and customer delays. (Pages 3, 13)
- →Growth in specific high-potential segments such as bioprocessing, semiconductor-related ultra-pure water, and industrial automation is expected to fuel future revenue expansion. (Pages 3, 12, 13)
- →China and emerging markets like India are showing good momentum and contributing to growth expectations. (Pages 3, 8, 13)
- →Service revenue is growing strongly (7% in Q1), with opportunities to increase attach rates and cover more of the installed base. (Page 10)
- →Product innovation and reshoring trends are additional growth drivers anticipated over the medium term. (Pages 6, 11, 12)
📈 Profitability & Margins
Rank 3- →**Full-year 2026 local currency sales growth**: Approximately 4%, including about 1.5% contribution from acquisitions in H1 and less than 8% for full year.
- →**Adjusted EPS for 2026**: Forecasted in the range of $46.30 to $46.95, representing 8% to 10% growth, an increase from prior guidance of 8% to 9%.
- →**Q2 2026 local currency sales growth**: Expected around 3%, including 1.5% from acquisitions.
- →**Q2 2026 adjusted EPS**: Expected in the range of $10.70 to $10.85, growth of 6% to 8%.
- →**Adjusted operating profit**: Increased 4% in Q1; operating margin guidance remains positive despite tariff and inflation headwinds.
- →**Service revenue**: Growing steadily, with 7% growth in Q1, indicating recurring revenue strength.
- →**Outlook**: Confidence in strong execution, innovation, and capturing growth from automation, digitalization, and onshoring trends despite macro uncertainties.
🏗️ Capital Expenditure Plans
Yes- →The company received a $6 million grant from the local government in Shanghai encouraging expansion of capacity, local manufacturing, and research (Page 13).
- →The grant includes CapEx-related and OpEx-related components, with CapEx part supporting capacity expansion (Page 13).
- →There is a focus on investments in innovations such as the R&D accelerator and JetStream programs to increase the pace of innovation, especially in high-growth segments like bioprocessing (Page 3).
- →The company is investing in automation and digitalization solutions to address growing demand in industrial and pharma markets (Pages 11 & 12).
- →While no specific future CapEx guidance is detailed, the company’s strategic investments include expanding manufacturing footprint in China and enhancing innovation capabilities to support growth (Pages 3, 11 & 13).
💰 Fundraising & Capital Structure
No information- →The document does not mention any current or planned new fundraising through debt or equity.
- →Share repurchases are expected in the range of $825 million to $875 million, indicating capital return rather than raising new equity.
- →Interest expense is forecast at approximately $70 million for the year, consistent with existing debt levels; no mention of new debt issuance.
- →No statements about issuing new equity or taking on additional debt for fundraising purposes are noted.
- →Focus appears to be on organic growth, acquisitions, and optimizing existing financial resources rather than new fundraising.
📋 Order Book & Pipeline
Yes- →The company typically carries about 1.5 months of backlog, which limits visibility from orderbook length.
- →They track multiple KPIs across the sales funnel from opportunities to orders but do not disclose specific backlog numbers.
- →Recent reviews with executive teams and the Board suggest increased pipeline activity compared to earlier in the year.
- →Despite geopolitical uncertainties causing some customer delays, there have been no cancellations; delays appear as pushouts rather than losses.
- →The increased funnel activity supports optimism for better growth conversion in the second half of the year.
- →The company feels confident about converting pipeline opportunities to orders unless geopolitical factors deteriorate further.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- West Pharmaceutical Services, Inc. (Q2 FY26)
West Pharmaceutical Services, Inc. Q2 FY26 quarterly results analysis. Revenue growth guidance for 2026 increased to 7% to 9% organic growth, reflecting strong
Frequently Asked Questions
What were Mettler-Toledo International Inc. Q2 FY26 results?
- The company expects local currency sales growth of approximately 4% for full year 2026, including about 1.5% contribution from acquisitions in H1 and less than 8% for the full year. - **Full-year 2026 local currency sales growth**: Approximately 4%, including about 1.5% contribution from acquisitions in H1 and less than 8% for full year.
What is Mettler-Toledo International Inc. share price analysis?
Mettler-Toledo International Inc. currently shows a neutral. The stock trades at a P/E of 25.9 with a market cap of $23,512. Investors should review the full earnings analysis for detailed insights.
Is Mettler-Toledo International Inc. planning capital expenditure?
- The company received a $6 million grant from the local government in Shanghai encouraging expansion of capacity, local manufacturing, and research (Page 13).
Keep Mettler-Toledo International Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.